Skip to content

Effect of interfron in the treatment of covid

Effect of interfron in the treatment of covid

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230930059562N1
Enrollment
80
Registered
2023-10-06
Start date
2021-01-21
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid pneumonia. Coronavirus as the cause of disease

Interventions

Intervention 1: "Intervention group:" people receiving recigen brand interferon beta with a dose of 12m iu eq daily for 5 days along with other common corona treatments including hydroxychloroquine 20

Sponsors

Imam hossein hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with Covid pneumonia who needs to hospitalised

Exclusion criteria

Exclusion criteria: Oxygen saturation percentage above 89%

Design outcomes

Primary

MeasureTime frame
Duration of hospitalization and ambient blood oxygen saturation percentage and duration of icu needed in patients who receive interferon. Timepoint: All the time spent in hospital. Method of measurement: Investigating the effect of interferon in the treatment of corona by calculating the percentage of ambient blood oxygen and the duration of hospitalization by pulse oximetry and observing the patient's clinical condition.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Rahmani

Shahid Beheshti University of Medical Sciences

Roya.rahmani89@gmail.com+98 912 465 5324

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026